Casein Kinase 1 alpha (CSNK1A1) Rabbit Polyclonal Antibody

CAT#: TA323098

Anti-CSNK1A1 Rabbit Polyclonal Antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Transient overexpression lysate of casein kinase 1, alpha 1 (CSNK1A1), transcript variant 1
    • 100 ug

CNY 3,080.00


Transient overexpression lysate of casein kinase 1, alpha 1 (CSNK1A1), transcript variant 2
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Applications IHC, WB
Recommend Dilution WB: 200-1000
WB positive control: A549 cells
IHC: 25-100
Positive control: Human prostate cancer
Predicted cell location: Cytoplasm
Reactivity Human, Mouse
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide corresponding to a region derived from 316-329 amino acids of Human Casein kinase I isoform alpha
Formulation PBS pH7.3, 0.05% NaN3, 50% glycerol
Concentration lot specific
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name casein kinase 1 alpha 1
Background Casein kinase; a ubiquitous; well-conserved protein kinase involved in cell metabolism and differentiation; is characterised by its preference for Serine or Threonine in acidic stretches of amino acids. The enzyme is a tetramer of 2 alpha- and 2 beta-subunits.The alpha-subunit is the catalytic unit and contains regions characteristic of serine/threonine protein kinases.
Synonyms CK1; CK1a; CKIa; HEL-S-77p; HLCDGP1; PRO2975
Reference Data
Protein Families Druggable Genome, ES Cell Differentiation/IPS, Protein Kinase
Protein Pathways Hedgehog signaling pathway, Wnt signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...